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Reports  on  the  implementation  of  the  Directive  on  the  application  of  Patients’  Rights  in Cross-border
Healthcare indicate  that  it had  little  impact  on  the  numbers  of  patients  seeking  care  abroad.  We  set  out
to explore  the effects  of this  directive  on health  systems  in seven  EU Member  States.  Key  informants
in  Belgium,  Estonia,  Finland,  Germany,  Malta,  Poland  and  The  Netherlands  ﬁlled  out  a structured  ques-
tionnaire.  Findings  indicate  that  the  impact  of the  directive  varied  between  countries  and  was  smaller
in  countries  where  a large  degree  of adaptation  had  already  taken  place  in response  to the  European
Court  of  Justice  Rulings.  The  main  reforms  reported  include  a  heightened  emphasis  on patient  rights
and  the adoption  of explicit  beneﬁts  packages  and  tariffs.  Countries  may  be facing  increased  pressure
to  treat  patients  within  a medically  justiﬁable  time  limit.  The  implementation  of  professional  liability
insurance,  in  countries  where  this  did  not  previously  exist,  may  also  bring  beneﬁts  for  patients.  Lower-
ing  of reimbursement  tariffs  to dissuade  patients  from  seeking  treatment  abroad  has  been  reported  in
Poland.  The  issue  of  discrimination  against  non-contracted  domestic  private  providers  in  Estonia,  Finland,
Malta and  The  Netherlands  remains  largely  unresolved.  We  conclude  that  evidence  showing  that  patients
using  domestic  health  systems  have  actually  beneﬁtted  from  the  directive  remains  scarce  and  further
monitoring  over  a longer  period  of  time  is recommended.
©  2018  The  Author(s).  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the CC. Introduction
Directive 2011/24/EU of the European Parliament and of thePlease cite this article in press as: Azzopardi-Muscat N, et 
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ouncil of 9 March 2011 on the application of patients’ rights
n cross-border healthcare (hereafter referred to as the directive)
ntered into force on 24 April 2011 and had to be transposed into
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168-8510/© 2018 The Author(s). Published by Elsevier B.V. This is an open access articl
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
national law until 25 October 2013 [1]. At the time of its develop-
ment and adoption, the directive was  considered contentious since
it is the ﬁrst legislative foray by the European Commission speciﬁ-
cally drafted for the area of health services. The directive had been
originally triggered by a series of rulings of the Court of Justice of
the European Union since 1998 and the thwarted efforts to respond
to these through the so called ‘Bolkestein’ services directive, which
aimed to treat health services as a ‘normal’ service [2],[3]. From the
start of the original court rulings in 1998 until the adoption of theal. The role of the 2011 patients’ rights in cross-border
s: Looking beyond patient mobility. Health Policy (2017),
directive and its transposition into national law, ﬁfteen years had
elapsed. During this period the European Union underwent impor-
tant transformations and the context within which the directive
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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directive. A summary of the effects on key dimensions pertaining
to patients’ rights is presented in Table 1.1ARTICLEEAP-3839; No. of Pages 5
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as being implemented was that of a Europe in the midst of a severe
conomic recession with many Member States implementing harsh
usterity programmes including health sector budgetary cuts. [4]
n addition, the ﬁnancial sustainability of several Member States’
ealth systems came under scrutiny of the European Semester pro-
ess and Country Speciﬁc Recommendations. [5] The directive was
herefore implemented in an environment that was somewhat hos-
ile and sceptical to the possibility of external European pressures
mpacting signiﬁcantly on health care budgets. Reports document-
ng minimalist approaches to transposition [6–10] as well as the
arge number of infringement procedures initiated by the European
ommission provide evidence of this effect. A report issued by the
uropean Commission in 2015 [11] as well as a Eurobarometer sur-
ey in the same year both point towards the directive having made
ittle impact on increasing patient mobility in the European Union
12]. It seems that cultural, language and ﬁnancial barriers are sim-
ly too high to turn patient mobility into a larger phenomenon
13]. One may  therefore pose the question, to what extent did the
irective actually provide beneﬁts for European patients?
Some have argued that the intrinsic value of this directive may
ave far more to do with the indirect ‘Europeanising’ effects that the
irective may  have on the domestic health systems [14], [15] Whilst
t is not the scope of this paper to delve into the detail of the theory
f Europeanisation, [16] the promotion of patients’ rights has been
escribed as a common European health system value [17] and the
hanges in domestic legislation, policies and institutions to further
romote the concept of patients’ rights can therefore be considered
s a ‘Europeanising’ effect [18]. In this paper we therefore choose
o focus on an analysis of the effects of the directive on patients
ho make use of health services in their domestic health system.
peciﬁcally we seek to document whether any changes in terms of
ccess or quality improvement measures linked to patients’ rights,
ave been observed in association with the implementation of the
irective.
. Methods
A structured questionnaire was ﬁlled out by key informants
n Belgium, Estonia, Finland, Germany, Malta, Poland and The
etherlands during 2015. The countries were selected to reﬂect
he diversity of EU health systems in terms of size, geography,
conomic development, type of health system and degree of sup-
ort or resistance to adoption of the directive at voting stage in
he Council of the European Union. Key informants were identi-
ed from the Observatory on Health Systems and Policies’ network
f experts, including its Health Systems and Policy Monitor net-
ork (www.hspm.org). There were 1–2 experts per country, who
orked together in completing the questionnaire. Experts were
hosen on having a deep insight into the policy process in their
ountry through involvement in research and policy development
nd a track record in the ﬁeld of cross-border care. Data collec-
ion took place between June and October 2016 and comprehensive
esponses were received from each of the ﬁve countries. For Malta
nd Germany, the coordinating authors ﬁlled in the question-
aire. Experts were asked to provide information about legislation
dopted, new institutions created and other unforeseen effects that
ay  have arisen within the domestic health systems as a result of
he implementation of the directive. Experts were given a check-
ist of areas comprising elements that feature in the directive to
nhance comparability of the ensuring analysis (see Box 1).
The framework from the “Europeanisation” theory regardingPlease cite this article in press as: Azzopardi-Muscat N, et 
health care directive in shaping seven national health system
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oodness of ﬁt was applied to describe the ﬁndings that emerged
19], [20]. This framework predicts that depending on the degree
f misﬁt between the proposed EU legislation and the situation
n the Member State, Member States will respond accordingly. A PRESS
 Policy xxx (2017) xxx–xxx
low degree of misﬁt is expected to lead to minimal upheaval with
adoption and adaptation taking place. A high degree of misﬁt on
the contrary is expected to generate one of two scenarios. Member
States may  use the opportunity afforded by the need to transpose
EU legislation in order to bring about transforming effects into their
domestic system, by changing legislation, institutions and policies
to fully assimilate the EU directive and additionally implement
desired changes that may  even go beyond the minimum direc-
tive requirements. Alternatively, the high degree of misﬁt may be
viewed as being too costly to adapt to and Member States engage
in policy behaviour that has been described as ‘inertia’ or ‘retrench-
ment’ [19].
3. Results
This section will ﬁrst discuss the implementation of the direc-
tive. We  then highlight those areas where actual changes occurred
in the domestic health systems across countries and that were
reported to be related to the implementation of the directive. The
impact on patients’ rights is presented. Lastly, we look at individ-
ual countries, the dominant changes and policy debate and seek to
situate these ﬁndings within the ‘goodness of ﬁt’ framework [19].
3.1. Implementation of the directive
Implementation of the directive appears to have generally
followed the patterns predicted by the goodness of ﬁt theory.
In Member States such as Belgium, Estonia, Germany, and the
Netherlands, generally speaking minimal impacts of the directive
have been reported since these countries had been early adopters of
the ECJ case law on patient mobility. Germany and the Netherlands
for example, already brought national legislation in line with case
law in 2004. Moreover, Belgium, Germany, and the Netherlands
operate multiple payer health insurance systems, which mean that
they already had rather explicitly deﬁned beneﬁt packages, reim-
bursement amounts and rules [3]. Estonia, which operates a single
payer insurance system, also reportedly had a relatively smooth
implementation of the directive since the beneﬁts package and
reimbursement rules were already in place.
On the other hand, Member States such as Poland, Malta and
to a lesser extent, Finland appear to have had to implement larger
health system adaptations. These countries had not taken signif-
icant steps to implement ECJ rulings prior to the transposition
of the directive. With the exception of Poland, they are National
Health Service type health systems, which historically have not
had explicitly deﬁned beneﬁt packages and reimbursement rules,
and therefore had a greater degree of misﬁt with the proposals in
the directive [21]. The Polish and Maltese authorities also feared
that long domestic waiting times could provide another motiva-
tion to seek care abroad. Furthermore, the authorities in Estonia
and Poland, both countries with relatively low spending and pric-
ing levels feared that the directive would encourage patients to seek
expensive care abroad. An upsurge in patients seeking care abroad
would imply an outﬂow of public funding that could threaten the
ﬁnancial sustainability of the domestic system. These reasons com-
bined greatly affected the attitude taken in the transposition of theal. The role of the 2011 patients’ rights in cross-border
s: Looking beyond patient mobility. Health Policy (2017),
1 This table uses a framework from work carried out on patients rights which is
in  the process of being published. Appropriate citation will be provided shortly.
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Table  1
Overview of ﬁndings on the implementation of the directive in relation to patients’ rights.
Patients’ rights Belgium Estonia Finland Germany Malta Netherlands Poland
Access to health care legal framework
with regard to
prior authorisation
for care abroad was
revised.
adoption of an
explicit beneﬁts
package
adoption of an
explicit beneﬁts
package
Attempts to lower
waiting times for
oncology patients
Monitoring waiting
times
setting up of the
Council for Choices
in Health Care
newly established
Advisory
Committee on
Health Beneﬁts
reduce access for
cataract surgery by
reduced
reimbursement
and higher severity
levels
18 months waiting
time adopted
Choice access to domestic
private providers
(discussed)
access to domestic
private providers
(discussed)
access to domestic
private providers
(discussed)
access to domestic
private providers
(discussed)
access to domestic
private providers
(discussed)
Information lay  information on
patients’ rights
improve transparency
about quality and cost
(parallel development)a  law providing
transparency on
the applied tariffs
for care and the
reimbursable
amount was
enacted.
Flemish Indicators
project comparing
quality aspects
amongst hospitals
Redress mandatory
professional
liability insurance
existing liability
insurance adapted
mandatory
professional
liability insurance
mandatory
professional
liability insurance
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.2. Changes and trends across health systems
Turning speciﬁcally to the situation of patients’ rights within
he domestic health system the following developments have
een reported. Malta reports that speciﬁc reference was  made to
atients’ Rights in a new legislative act for the ﬁrst time [22].
n addition, Finland and Malta report the adoption of an explicit
eneﬁts package. In Finland this entailed the setting up of the
ouncil for Choices in Health Care whose mandate went beyond
he requirement of the directive and includes the task of priority
etting. In Malta, responsibility for determination of the beneﬁts
ackage was given to the newly established Advisory Committee
n Health Beneﬁts whose remit also includes prioritisation and
se of health technology assessment. Whilst patients can beneﬁt
rom this increased transparency, the issue of explicit treatment
ationing can also be an alternative consideration in this situation.
The introduction of mandatory professional liability insurance
n Malta and in Poland (in 2012) can also be viewed as an exam-
le of a patient rights and empowerment mechanism as patients
re in a stronger position to claim compensation and redress. In
stonia, while mandatory professional liability insurance has not
et been introduced, it is expected to be implemented during com-
ng years and the directive has reportedly played an important role
o foster this process. In Germany, existing liability insurance had
o be adapted and incorporated that physicians who  do not have
ufﬁcient liability coverage can be suspended.
The issue of access to domestic private providers that are
ot contracted by the public system was mentioned by Estonia,Please cite this article in press as: Azzopardi-Muscat N, et 
health care directive in shaping seven national health system
https://doi.org/10.1016/j.healthpol.2017.12.010
alta, Finland, the Netherlands and Poland. Different approaches
o this issue were reported in the different Member States.
lthough the Directive does not require opening up funding to
omestic private providers operating in the private market, theseimplemented implemented
providers argue that they would be discriminated if the direc-
tive gives patients access to foreign private providers but not to
non-contracted domestic private providers. This phenomenon, is
commonly referred to in European law as reverse discrimination.
This arises when nationals/service providers of a Member State
are disadvantaged because they are subject to a national measure,
while foreign (EU) nationals/service providers are protected from
that national measure by virtue of EU law [23]. However, to date,
none of the Member States studied has allowed open access to
domestic providers on an equal basis as non-contracted health care
providers in another country due to indirect pressure that emerged
as a response to the Directive.
The issue of waiting times has played an important role in
ECJ case law on patient mobility [24]. The directive incorporates
this aspect such that if health care cannot be provided domesti-
cally within a medically justiﬁable time limit, which depends on
a person’s condition, an authorisation cannot be refused. In the
countries studied we  have found no establishment of maximum
waiting times as a result of the directive. Estonia, Finland and the
Netherlands already operate such systems, while German author-
ities view this as unnecessary. In Poland however attempts have
been made to lower waiting times for oncology patients (without
much effect) by increasing funding. In Malta a maximum 18 month
waiting time was  adopted in the Patients Charter in late 2016. The
need felt by the government to speciﬁcally establish a maximum
waiting time has been linked to the implementation of the directive
[25].al. The role of the 2011 patients’ rights in cross-border
s: Looking beyond patient mobility. Health Policy (2017),
3.3. Country speciﬁc debates and changes
Although Belgium was not required to make major changes
to its health system to implement the provisions of the direc-
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ive, domestic patients beneﬁtted from provisions clarifying their
ights. For example, patient-friendly lay information on patients’
ights was for the ﬁrst time presented in a systematic manner,
hrough the website of the national contact point. Furthermore,
 law providing transparency on the applied tariffs for care and the
eimbursable amount was enacted. The latter enables patients to
ompare out of pocket payments between providers and thus has
he potential to improve access to care. Some quality improving
nitiatives were facilitated by the directive, such as the Flemish Indi-
ators project where hospitals can compare speciﬁc quality aspects
mongst themselves. A working group has been ofﬁcially tasked
ith the elaboration of a system to monitor patients waiting times.
urthermore, another aspect of quality is the concentration of treat-
ents of rare cancers to a limited number of centres of reference
hat comply with certain quality standards. This proposal, which is
xpected to be implemented as part of a major hospital reform, was
ustiﬁed by making reference to the provisions concerning quality
nd centres of reference found in the EU Directive.
In Estonia, the issue of opening up access to non-contracted
omestic hospital providers through the provision of cash bene-
ts, which would amount to the domestic tariff of the particular
ervice, has been included in legislation. This was primarily due to
ressure from private providers rather than from patient groups
nd sought to address the existence of reverse discrimination. To
ate, however, the authorities have not taken steps to implement
his measure in practice due to three sets of concerns. It is feared
hat this new beneﬁt [1] may  undermine equity and widen exist-
ng inequalities because it is paid only retrospectively, [2] may  draw
apacity away from contracted providers and lead to waiting lists
or those who rely on beneﬁts in kind, and [3] may  make it difﬁcult
or the Estonian Health Insurance Fund to control quality and over-
ll expenditure. Thus in Estonia the phenomenon of discrimination
gainst domestic private providers persists.
In Finland, a two-tier system for reimbursement of care from
ublic providers and non-contracted private domestic providers
xists. The domestic social insurance level is applied if the patient
ecides to go abroad to use health services and does not have a
rior authorisation. If the use is due to an urgent need for care
hen otherwise travelling in another EU/EEA country or the patient
as authorisation, the costs are covered according to the public
ector tariff in the country of treatment. In order not to disad-
antage domestic private providers, in its transposition of the
irective Finland chose to reimburse overseas providers on the
ame level as its domestic private providers so as not to create
 situation of reverse discrimination. This was not deemed to be
n conformity with the directive by the European Commission.
he Finnish Government is preparing a health and social care and
ocal/regional government reform. The planned reform includes the
bolishment of the health insurance reimbursement for the use of
rivate services. Since the overseas reimbursement tariff has been
inked to the domestic private reimbursement rate, it remains to
e seen what wider effects this reform could have. Therefore with
espect to the position of access to domestic non-contracted pri-
ate providers, the directive has not had an effect on opening up
ccess for patients in their home health care systems to date.
Germany, was not required to implement major changes to its
ealth system as an early adopter of relevant case law, other than
o set up a national contact point and centralize certain information
hat was before mostly available from individual sickness funds and
egional authorities. German authorities had no concerns regard-
ng increased mobility from and to Germany and potential negative
ffects for domestic patients in terms of accessibility. In addition,Please cite this article in press as: Azzopardi-Muscat N, et 
health care directive in shaping seven national health system
https://doi.org/10.1016/j.healthpol.2017.12.010
aiting times never formed a pressing issue due to the broad range
f well accessible services available while initiatives to improve
ransparency about quality and cost were already underway. This
ogether perhaps explains why it was implemented without much PRESS
 Policy xxx (2017) xxx–xxx
public and political debate. Small adaptations were however nec-
essary in state level liability insurance regulations, not because
they were currently insufﬁcient, but because the directive focused
on personal liability insurance, while in Germany there are other
mechanisms, e.g. reserves held at the hospitals, to cover liability.
Leaving current state regulations untouched could have led to sus-
pension of physicians although de facto enough liability coverage
was available.
In Malta, a Parliamentary motion calling to open up the health
system to private providers in cases of undue delay was  defeated
in 2014. In 2016, the Ministry for Health adopted a Patient Char-
ter which includes the provision that persons waiting for longer
than 18 months will be able to access the domestic private sector
under similar terms and conditions as those provided for access to
overseas non-contracted providers under the directive. This is the
ﬁrst time an explicit waiting time target has been introduced. The
political commitment to introduce maximum waiting times was a
government electoral programme initiative. It is difﬁcult to ascer-
tain to what extent the implementation of the directive played a
role in inﬂuencing the implementation of this policy measure.
Similarly to the situation in Germany, the directive did not
necessitate large changes in the Netherlands. However, attempts
were made by Government to scale back the existing rights to
access care from non-contracted providers and be reimbursed
75–80% of the cost. These were met by strong opposition fearing
that it would give too much power to insurers to decide what care
is good enough as well as concern that they would not be in line
with the Directive. Finally, the status quo position was preserved
[26]. In this sense, the Directive indirectly helped to safeguard that
patients in the Dutch health care system continue to exercise the
wide choice they were previously accustomed to.
In Poland, patients may  actually have been negatively affected
by the directive when using domestic health services [27]. Reim-
bursement tariffs for cataract operations were reduced and the
threshold to qualify for cataract surgery, which is described in terms
of severity of impairment, was heightened. It is believed that this
measure was implemented as a safeguard to dissuade patients from
seeking care for this condition outside Poland. The large difference
between the cost abroad and the actual reimbursement tariff would
be of such magnitude that patients may  prefer to wait to access care
within their own system rather than face the extra cost of the non-
reimbursed portion of care. The revision of the threshold for access
to surgery was  an indirect method to curb demand, hence reduc-
ing waiting times, but does little to solve a real and existing health
need in the country.
4. Discussion
Further to the implementation of the directive, European
patients may  beneﬁt from a more explicit and thus transparent
description of beneﬁts packages where this was hitherto not the
case. This increases access to comparability of beneﬁts packages
thereby equipping patient groups with information to advocate
for introduction of additional beneﬁts, indirectly setting normative
benchmarks for health services. The introduction of professional
indemnity insurance where this was previously unavailable also
facilitates right of redress and compensation. Moreover, although
we do not ﬁnd direct evidence that countries have deﬁned maxi-
mum waiting times as a direct result of the directive, the directive
does put a certain pressure on European health systems to not
run up waiting times beyond a medically justiﬁable time limit.al. The role of the 2011 patients’ rights in cross-border
s: Looking beyond patient mobility. Health Policy (2017),
Although this is generally beneﬁting to patients, countries could
also respond by heightening the indication thresholds to shorten
waiting times, as was visible in the Polish cataract case, or to remove
certain procedures from the beneﬁt basket altogether.
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The topic of access to domestic private providers is a com-
lex one. It is recognised that in certain countries the directive
as created a situation where domestic non-contracted providers
re discriminated as patients are able to access services from
on-contracted providers abroad and claim reimbursement but
re unable to do so within their domestic health system. Qual-
ty, equity and sustainability considerations have arisen and as a
esult Governments have been reluctant to change the nature of
heir health systems where domestic non-contracted providers are
o date excluded. The Polish case stands out as an example where
atients may  have been negatively affected by the directive and
ccess to certain services is impeded. It seems that strict monitoring
f such cases is needed.
This study has attempted to document the domestic impacts
hat implementation of the cross-border directive has had on seven
U health systems. It is limited to experts providing country reports
ased mostly on grey literature and national data sources and
herefore the ﬁndings must be interpreted within these caveats.
. Conclusion
The overall picture obtained from the reports on implementa-
ion of the patients’ rights and cross-border care directive in the
even Member States studied is one in which the directive has not
ad some major transformative effect on domestic health systems.
n The Netherlands, Germany and Belgium the domestic health sys-
ems already had the required systems in place and as predicted by
he goodness of ﬁt framework minimal domestic changes were by
nd large easily accommodated. Estonia, Finland, Malta and Poland
ad to introduce certain changes to meet the cross-border care
irective requirements, but there is no evidence of leveraging the
irective to bring about major changes in the domestic health sys-
ems. Indeed the behaviours adopted can better be described in
erms of policy inertia and retrenchment.
The introduction of patients’ rights legislation, a larger emphasis
n transparency and the issue of access to non-contracted domes-
ic providers could all potentially serve to change policies around
ccess to domestic health services in the long run. Some efforts
o improve quality in health systems can also be linked to spe-
iﬁc initiatives listed in the Directive, e.g. centres of reference and
-health.
We conclude that whilst the directive has triggered the imple-
entation of some measures related to patients’ rights, waiting
imes and quality of care that may  intuitively lead to beneﬁts for
atients seeking health care in their domestic health systems, to
ate, evidence showing that patients have actually beneﬁtted from
uch measures remains scarce and further monitoring over a longer
eriod of time is recommended. In that light, the EU’s increased
nterest in monitoring waiting times across Europe is a good ini-
iative but it could perhaps also be extended to include changes in
eneﬁt baskets, tariffs and coverage.
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